Business
Innovest Global, Inc. Looks To Capitalize On Resurgent Biotech Industry -- Spotlight Growth
Innovest Global, Inc. Looks To Capitalize On Resurgent Biotech Industry -- Spotlight Growth.
About this update from Innovest Global Inc
[{"type":"text","content":"\n\n Sacramento, CA, March 13, 2018 (GLOBE NEWSWIRE) -- A new report has been published on Innovest Global, Inc. (OTC Pink: IVST). Innovest Global, Inc. is a diversified holding company that focuses on acquiring niche, high-growth businesses that are capable of generating significant annual revenue. The company’s planned subsidiaries operate across biotechnology & health sciences, commercial & industrial energy and distribution, auto sales, a national call center, and more.\n The report provides an overview of biotechnology’s past performance, outlook, developments, industry trends, industry equity research reports, and Innovest’s recently announced move to form a biotech and health sciences division. Morningstar: Biotech Positioned to Return to Long-Term Market Outperformance The health sector has been one of the top performers over the past many decades. In fact, the health sector has been generating an annualized rate of return of 11% since 1963. Only consumer staples managed to have greater return figures during the same time period.  Morningstar analysts note that the biotech industry has seen three major cycles thus far: first cycle came in late 1990s, second in mid-2000s, and latest cycle took place between 2012 and 2016. The analysts note that a perfect storm of bearish activity began to overtake biotech in early 2015, which has led to a period of underperformance. Exacerbated valuations, ending drug cycles, and a tumultuous U.S. presidential election helped push biotech stocks down the past couple of years.  However, research analysts and fund managers are increasingly interested in the growing resurgence within the industry. Among the key factors driving the rebound are development of revolutionary new drugs, the aging American population, and slashing regulatory hurdles at the U.S. Food and Drug Administration (FDA). Dale Chan, manager of Prudential Jennison Health Sciences mutual fund, says he sees innovation \"across all kinds of interesting areas,\" including in oncology-related gene therapies and around depression, muscular sclerosis, and epilepsy treatments.  However, Mr. Chan notes that he sees a vast majority of the biotech innovation being accomplished by small- and mid-cap stocks. While larger stocks will serve as better valuation-based opportunities, according to the ...